Clinical Trial Detail

NCT ID NCT02528357
Title GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

colorectal cancer

Advanced Solid Tumor

sarcoma

urinary bladder cancer

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

melanoma

Therapies

GSK3174998

Pembrolizumab

Age Groups: adult

No variant requirements are available.